Low dosage of rasagiline and epigallocatechin gallate synergistically restored the nigrostriatal axis in MPTP-induced parkinsonism

Neurodegenerative Diseases

Volumn 7, Issue 4, 2010, Pages 219-231

  Reznichenko, Lydia ^a   Kalfon, Limor ^a   Amit, Tamar ^a   Youdim, Moussa B H ^a   Mandel, Silvia A ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Brain derived neurotrophic factor; Disease modifying therapy; Green tea; N methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Neurorescue; Parkinson's disease; Protein kinase C; Rasagiline

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BRAIN DERIVED NEUROTROPHIC FACTOR; EPIGALLOCATECHIN GALLATE; PROTEIN KINASE B; PROTEIN KINASE C ALPHA; RASAGILINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LEVEL; CELL LOSS; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MALE; MOUSE; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; WESTERN BLOTTING;

ANIMALS; ANTIOXIDANTS; CATECHIN; CELL LINE; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG SYNERGISM; INDANS; MALE; MICE; MICE, INBRED C57BL; NEURAL PATHWAYS; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS; RECOVERY OF FUNCTION; SUBSTANTIA NIGRA; TREATMENT OUTCOME;

EID: 77953808064     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000265946     Document Type: Article

References (53)

1. Fahn S: Description of Parkinson's disease as a clinical syndrome. Ann NY Acad Sci 2003; 991: 1-14.
2. Youdim MB, Gross A, Finberg JP: Rasagiline [N-propargyl-1R(+)-aminoindan] , a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 2001; 132: 500-506.
3. Parkinson Study Group: A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004; 61: 561-566.
4. Olanow CW, Hauser RA, Jankovic J, Langston W, Lang A, Poewe W, Tolosa E, Stocchi F, Melamed E, Eyal E, Rascol O: A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the Adagio Study): rationale, design, and baseline characteristics. Mov Disord 2008; 23: 2194-2201.
5. Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E: A doubleblind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009; 361: 1268-1278.
6. Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC: Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl- 1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 1984; 311: 467-469.
7. Youdim MBH, Wadia A, Tatton W, Weinstock M: The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann NY Acad Sci 2001; 939: 450-458.
8. Weinreb O, Bar-Am O, Amit T, Chillag- Talmor O, Youdim MB: Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J 2004; 18: 1471-1473.
9. Bar-Am O, Weinreb O, Amit T, Youdim MB: Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J 2005; 19: 1899-1901.
10. Maruyama W, Nitta A, Shamoto-Nagai M, Hirata Y, Akao Y, Yodim M, Furukawa S, Nabeshima T, Naoi M: N-Propargyl-1 (R)-aminoindan, rasagiline, increases glial cell linederived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor. Neurochem Int 2004; 44: 393-400.
11. Sagi Y, Mandel S, Amit T, Youdim MB: Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism. Neurobiol Dis 2007; 25: 35-44. (Pubitemid 44765215)
12. Zhu W, Xie W, Pan T, Jankovic J, Li J, Youdim MB, Le W: Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration. J Neurochem 2008; 105: 1970-1978.
13. Carlile GW, Chalmers-Redman RM, Tatton NA, Pong A, Borden KE, Tatton WG: Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer. Mol Pharmacol 2000; 57: 2-12.
14. Youdim MB, Maruyama W, Naoi M: Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline. Drugs Today (Barc) 2005; 41: 369-391.
15. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR: Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 2004; 5: 863-873.
16. Levites Y, Weinreb O, Maor G, Youdim MBH, Mandel S: Green tea polyphenol (-)-epigallocatechin-3-gallate prevents Nmethyl- 4-phenyl-1,2,3,6- tetrahydropyridine- induced dopaminergic neurodegeneration. J Neurochem 2001; 78: 1073-1082.
17. Mandel SA, Amit T, Weinreb O, Reznichenko L, Youdim MB: Simultaneous manipulation of multiple brain targets by green tea catechins: a potential neuroprotective strategy for Alzheimer and Parkinson diseases. CNS Neurosci Ther 2008; 14: 352-365.
18. Levites Y, Amit T, Youdim MBH, Mandel S: Involvement of protein kinase C activation and cell survival/cell cycle genes in green tea polyphenol (-)-epigallocatechin-3-gallate neuroprotective action. J Biol Chem 2002; 277: 30574-30580.
19. Reznichenko L, Amit T, Youdim MB, Mandel S: Green tea polyphenol (-)-epigallocatechin- 3-gallate induces neurorescue of longterm serum-deprived PC12 cells and promotes neurite outgrowth. J Neurochem 2005; 93: 1157-1167.
20. Kuriyama S, Hozawa A, Ohmori K, Shimazu T, Matsui T, Ebihara S, Awata S, Nagatomi R, Arai H, Tsuji I: Green tea consumption and cognitive function: a cross-sectional study from the Tsurugaya Project 1. Am J Clin Nutr 2006; 83: 355-361.
21. Checkoway H, Powers K, Smith-Weller T, Franklin GM, Longstreth WT Jr, Swanson PD: Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am J Epidemiol 2002; 155: 732-738.
22. Hu G, Bidel S, Jousilahti P, Antikainen R, Tuomilehto J: Coffee and tea consumption and the risk of Parkinson's disease. Mov Disord 2007; 22: 2242-2248.
23. Tan LC, Koh WP, Yuan JM, Wang R, Au WL, Tan JH, Tan EK, Yu MC: Differential effects of black versus green tea on risk of Parkinson's disease in the Singapore Chinese Health Study. Am J Epidemiol 2008; 167: 553-560.
24. Kandinov B, Giladi N, Korczyn AD: Smoking and tea consumption delay onset of Parkinson's disease. Parkinsonism Relat Disord 2009; 15: 41-46.
25. Dauer W, Przedborski S: Parkinson's disease: mechanisms and models. Neuron 2003; 39: 889-909.
26. Van der Schyf CJ, Gal S, Geldenhuys WJ, Youdim MB: Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases. Expert Opin Investig Drugs 2006; 15: 873-886.
27. Jackson-Lewis V, Przedborski S: Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc 2007; 2: 141-151.
28. Keller R, Oke A, Mefford I, Adams RN: Liquid chromatographic analysis of catecholamines routine assay for regional brain mapping. Life Sci 1976; 19: 995-1003.
29. Ben-Shachar D, Youdim MB: Selectivity of melaninized nigra-striatal dopamine neurons to degeneration in Parkinson's disease may depend on iron-melanin interaction. J Neural Transm Suppl 1990; 29: 251-258.
30. Hayley S, Crocker SJ, Smith PD, Shree T, Jackson-Lewis V, Przedborski S, Mount M, Slack R, Anisman H, Park DS: Regulation of dopaminergic loss by Fas in a 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Neurosci 2004; 24: 2045-2053.
31. Abercrombie M: Estimation of nuclear population from microtome sections. Anatomy 1946; 239-247.
32. Son JH, Chun HS, Joh TH, Cho S, Conti B, Lee JW: Neuroprotection and neuronal differentiation studies using substantia nigra dopaminergic cells derived from transgenic mouse embryos. J Neurosci 1999; 19: 10-20.
33. Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ: Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 1998; 64: 314-319.
34. Lamensdorf I, Youdim MBH, Finberg JP: Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. J Neurochem 1996; 67: 1532-1539.
35. Liu JP: Protein kinase C and its substrates. Mol Cell Endocrinol 1996; 116: 1-29.
36. Levites Y, Amit T, Mandel S, Youdim MBH: Neuroprotection and neurorescue against amyloid beta toxicity and PKC-dependent release of non-amyloidogenic soluble precursor protein by green tea polyphenol (-)-epigallocatechin-3- gallate. FASEB J 2003; 17: 952-954.
37. Skaper SD: The biology of neurotrophins, signalling pathways, and functional peptide mimetics of neurotrophins and their receptors. CNS Neurol Disord Drug Targets 2008; 7: 46-62.
38. Renton FJ, Jeitner TM: Cell cycle-dependent inhibition of the proliferation of human neural tumor cell lines by iron chelators. Biochem Pharmacol 1996; 51: 1553-1561.
39. Khan N, Afaq F, Saleem M, Ahmad N, Mukhtar H: Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin- 3-gallate. Cancer Res 2006; 66: 2500-2505.
40. Ravina BM, Fagan SC, Hart RG, Hovinga CA, Murphy DD, Dawson TM, Marler JR: Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology 2003; 60: 1234-1240.
41. NINDS NET-PD Investigators: A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 2007; 68: 20-28.
42. NINDS NET-PD Investigators: A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 2006; 66: 664-671.
43. Rascol O, Olanow CW: For the ADAGIO investigators. Abstract at the 12th Congr Eur Fed Neurol Soc, Madrid, 2008.
44. Hauser RA, Lew MF, Hurtig HI, Ondo WG, Wojcieszek J, Fitzer-Attas CJ: Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord 2009; 24: 564-573.
45. Du K, Tsichlis PN: Regulation of the Akt kinase by interacting proteins. Oncogene 2005; 24: 7401-7409.
46. Woodgett JR: Recent advances in the protein kinase B signaling pathway. Curr Opin Cell Biol 2005; 17: 150-157.
47. Guo Q, Zhao B, Li M, Shen S, Xin W: Studies on protective mechanisms of four components of green tea polyphenols against lipid peroxidation in synaptosomes. Biochim Biophys Acta 1996; 1304: 210-222.
48. Mandel S, Maor G, Youdim MB: Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate. J Mol Neurosci 2004; 24: 401-416.
49. Rezai-Zadeh K, Shytle D, Sun N, Mori T, Hou H, Jeanniton D, Ehrhart J, Townsend K, Zeng J, Morgan D, Hardy J, Town T, Tan J: Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci 2005; 25: 8807-8814.
50. Tanaka C, Nishino N, Hashimoto T, Kitamura N, Yoshihara C, Saito N: Second messenger systems in brains of patients with Parkinson's or Huntington's disease. Adv Neurol 1993; 60: 175-180.
51. Alkon DL, Sun M-K, Nelson TJ: PKC signaling deficits: a mechanistic hypothesis for the origins of Alzheimer's disease. Trends Pharmacol Sci 2006; 28: 51-60.
52. Mogi M, Togari A, Kondo I, Mizuno Y, Komure O, Kuno S, Ichinose H, Nagatsu T: Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. Neurosci Lett 1999; 270: 45-48.
53. Zhao C, Deng W, Gage FH: Mechanisms and functional implications of adult neurogenesis. Cell 2008; 132: 645-660.